Dendritic cells from bench to bedside and back

Immunology Letters

Volumn 122, Issue 2, 2009, Pages 128-130

  Adema, G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Toll like receptors; Vaccines

Indexed keywords

CANCER VACCINE; CORTICOSTEROID; FLAGELLIN; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERFERON; INTERLEUKIN 10; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; TOLL LIKE RECEPTOR; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CELL THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; LANGERHANS CELL; LYMPH NODE; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CELL MOTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; TOLL-LIKE RECEPTORS;

EID: 73349123487     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.11.017     Document Type: Review

References (15)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
2. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 10 5 (2004) 475-480
3. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 5797 (2006) 268-274
4. Schreurs M.W., Eggert A.A., de Boer A.J., Vissers J.L., van Hall T., Offringa R., et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60 24 (2000) 6995-7001
5. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9 14 (2003) 5091-5100
6. Nair S.K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J.S., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6 9 (2000) 1011-1017
7. Van Tendeloo V.F., Ponsaerts P., Lardon F., Nijs G., Lenjou M., Van Broeckhoven C., et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98 1 (2001) 49-56
8. Adema G.J., de Vries I.J., Punt C.J., and Figdor C.G. Migration of dendritic cell based cancer vaccines: in vivo veritas?. Curr Opin Immunol 17 2 (2005) 170-174
9. De Vries I.J., Krooshoop D.J., Scharenborg N.M., Lesterhuis W.J., Diepstra J.H., Van Muijen G.N., et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63 1 (2003) 12-17
10. Romero P., Dunbar P.R., Valmori D., Pittet M., Ogg G.S., Rimoldi D., et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188 9 (1998) 1641-1650
11. de Vries I.J., Bernsen M.R., Lesterhuis W.J., Scharenborg N.M., Strijk S.P., Gerritsen M.J., et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23 24 (2005) 5779-5787
12. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
13. Grauer O.M., Nierkens S., Bennink E., Toonen L.W., Boon L., Wesseling P., et al. CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121 1 (2007) 95-105
14. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2008.
15. 2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57 11 (2008) 1589-1597